ArticleJournal of clinical laboratory analysis2004
Technical and clinical evaluation of anti-ribosomal P protein immunoassays.
Article in Journal of clinical laboratory analysis, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05179018 (Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus: Case Control Study
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- CytoBead ANA 2 assay - a novel method for the detection of antinuclear antibodies.Scientific reports · 2025Article
- Anti-ribosomal P (anti-P) antibodies in patients with autoimmune hepatitis.Einstein (Sao Paulo, Brazil) · 2023Article
- The conundrum of neuropsychiatric systemic lupus erythematosus: Current and novel approaches to diagnosis.Frontiers in neurology · 2023Review
- The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV).Clinical rheumatology · 2022Article
- Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.Journal of translational autoimmunity · 2022Article
- Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.Arthritis care & research · 2019Article
- Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile.BMC medicine · 2013Article
- Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.Journal of clinical laboratory analysis · 2013Article
- Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent.Auto- immunity highlights · 2012Review
- Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope.Rheumatology international · 2012Article
- Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus.Arthritis research & therapy · 2011Article
- Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies.Arthritis research & therapy · 2008Article
- Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis.The Journal of experimental medicine · 2007Article
- Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection.Journal of molecular medicine (Berlin, Germany) · 2007Article
- International multicenter evaluation of autoantibodies to ribosomal P proteins.Clinical and vaccine immunology : CVI · 2006Article
- Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus.Clinical and experimental immunology · 2005Article
- Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay.Clinical and diagnostic laboratory immunology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies to the three ribosomal phospho (-P) proteins P0, P1, P2, referred to as Rib-P, are specifically found in 10-40% of patients with systemic lupus erythematosus. The variations in the observed frequency of these autoantibodies is related to a number of factors such as the test system used to detect the antibodies. Several immunoassays that were designed for research and diagnostic laboratory use have been developed. The autoantigens employed in these tests include native proteins, recombinant polypeptides, and synthetic peptides. In this study, we compared the technical and clinical accuracy of anti-Rib-P antibody assays from different commercial suppliers including ELISA systems and a novel addressable laser bead assay (from Euroimmun, MBL, Pharmacia Diagnostics, INOVA). Although the assays from all suppliers used in this study performed well in the technical part of the study, relatively poor correlations and significant differences in the clinical accuracy were found. Based on the results, we conclude that the detection of anti-Rib-P antibodies strongly depends on both the nature of the antigen and the detection system. We recommend that anti-Rib-P assays should be standardized on an international level. The Varelisa Rib-P profile and the addressable laser bead Rib-P assays represent promising tools and platforms for the detection of anti-Rib-P antibodies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.